INOVIQ Ltd (ASX:IIQ)

What INOVIQ Ltd (ASX:IIQ) does

INOVIQ Ltd (ASX:IIQ) is an Australian-listed biotechnology company developing exosome-based diagnostic and therapeutic products for cancer, headquartered in Notting Hill, Melbourne. The company commercialises two products: EXO-NET, an immuno-magnetic bead capture system for isolating extracellular vesicles from biofluids for research use only, and the hTERT ICC Test, an FDA Class I-listed immunocytochemistry assay used as an adjunct to urine cytology for bladder cancer detection with existing US reimbursement. Its underlying technology platforms include the NETs universal biomarker capture architecture, the SubB2M engineered protein that specifically binds the Neu5Gc pan-cancer biomarker, and the CAR-exosome therapeutic platform equipping exosomes with chimeric antigen receptors to target solid tumours.

Name

INOVIQ Ltd (ASX:IIQ)

Legal name

INOVIQ Ltd

Website

https://inoviq.com

Company type

Public

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

INOVIQ Ltd (ASX:IIQ) is an Australian-listed biotechnology company commercialising exosome-based diagnostics (EXO-NET research tool, FDA-listed hTERT ICC bladder cancer test) and developing a pipeline of cancer screening and CAR-exosome therapeutics for solid tumours.

Ownership category

akta.pro rank

Product category

Cancer Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Cytology & Histopathology Diagnostics (IHC, ISH, tissue-based assays) (HLAAALAI)

akta.pro secondary industries

Proteomics & Biomarker Analytical Testing (HLAGADAG), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB)

Keywords

• Exosome diagnostics
• Cancer screening tests
• Extracellular vesicle isolation
• Biomarker discovery tools
• Immunoaffinity capture technology

Headquarters

HQ city

Notting Hill

HQ country

Australia

HQ region

Oceania

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. EXO-NET® Product Sales: Sale of EXO-NET® Pan-Exosome Capture products for research use only (RUO). Products are sold in different sizes (60, 30, 15 isolations) at different price points.
2. hTERT ICC Test Sales: Sale of FDA Class I registered medical device - anti-hTERT antibody (SCD-A7) for detection of hTERT in cytopathology samples, used as adjunct to urine cytology for bladder cancer. Listed with FDA with existing reimbursement in USA.
3. EXO-NET Services and Licensing: ResearchDx provides EXO-NET® enabled high-throughput exosome isolation, biomarker discovery and diagnostics development services in the USA under licence. UniQuest agreement for EXO-NET® enabled exosome isolation and biomarker identification research.
4. EXO-OC™ Ovarian Cancer Screening Test (Pipeline): Next-generation exosome-based blood test in clinical development for screening ovarian cancer in asymptomatic women. Expected to be commercialised as LDT (Laboratory Developed Test) followed by IVD product.
5. CAR-Exosome Therapeutics (Pipeline): Preclinical CAR-exosome therapeutic program for solid tumours including Triple Negative Breast Cancer (TNBC) and ovarian cancer. Potential cell-free off-the-shelf therapy.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels7 records

Core offering

INOVIQ develops and commercialises exosome-based diagnostic and therapeutic products for cancer detection and treatment. The company has commercialised EXO-NET®, a pan-exosome capture research tool for isolating extracellular vesicles from body fluids, and the hTERT ICC Test, an FDA-listed Class I medical device used as an adjunct to urine cytology for bladder cancer detection. Its pipeline includes EXO-OC™, a clinical-stage ovarian cancer screening blood test, the NeuCA15-3 breast cancer monitoring test, and a preclinical CAR-exosome therapeutic program for solid tumours.

Product overview

INOVIQ Ltd is a medical diagnostics and biotechnology company that has commercialized two products and is developing a multi-product pipeline focused on cancer diagnostics and therapeutics. The commercial portfolio includes EXO-NET®, a pan-exosome capture tool for research use isolation of exosomes from body fluids, and the hTERT ICC Test, an FDA-listed Class I medical device used as an adjunct to urine cytology for bladder cancer detection. The development pipeline includes EXO-OC™, an exosome-based ovarian cancer screening test in clinical validation, and the NeuCA15-3 breast cancer monitoring test. The company is also developing CAR-exosome therapeutics for solid tumors. These products are powered by proprietary technology platforms including NETs (biomarker capture), SubB2M (cancer probe), and hTERT ICC assay technologies.

Differentiator

Problem solved

Functional benefit

Brands

• EXO-NET: Pan-exosome capture technology platform for research use isolation of extracellular vesicles from body fluids including plasma, urine, and saliva.
• EXO-OC
• ACURIS

Products and services

• EXO-NET® Pan-Exosome Capture An immunoaffinity magnetic bead-based isolation system for research use only (RUO) that enables fast, efficient and scalable isolation of exosomes from plasma, serum, urine, saliva and cell-conditioned medium for downstream biomarker analysis, sold to research laboratories and biotechnology companies.
• hTERT ICC Test An immunocytochemistry (ICC) assay that detects human telomerase reverse transcriptase (hTERT) and is used as an adjunct to urine cytology testing to help resolve indeterminate cytology results and identify patients with increased risk of bladder cancer; the anti-hTERT antibody (SCD-A7) is FDA-listed as a Class I medical device in the USA with existing reimbursement.
• EXO-OC™ Ovarian Cancer Screening Test A next-generation exosome-based blood test (liquid biopsy) in development for screening ovarian cancer in asymptomatic, average-risk women, using proprietary EXO-NET® technology to isolate exosomes combined with multiple biomarkers in an algorithm for early detection.
• NeuCA15-3 Test (SubB2M/CA15-3) A breast cancer monitoring test using SubB2M technology that detects the cancer biomarker Neu5Gc, with clinical validation demonstrating 81% sensitivity and 93% specificity for detecting breast cancer across all stages.
• CAR-Exosome Therapeutics A preclinical CAR-exosome therapeutic program for solid tumours, in which engineered exosomes are equipped with Chimeric Antigen Receptors (CARs) to target and kill cancer cells with potential safety, efficacy and cost advantages over CAR-T cell therapy.

Quantifiable outcome

• 100% sensitivity for early-stage (Stage I and II) ovarian cancer detection with >99.6% specificity across all stages
• +4 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Six partnerships are on record, tiered core and minor.

• Promega CorporationcoreChannel Partner/ Reseller/ DistributorGlobal Supply and Distribution Agreement for EXO-NET® products. Leading provider of innovative technologies, tools and technical support to the global life sciences industry. Agreement to market, distribute and sell EXO-NET alone or in combination with Promega Nucleic Acid purification systems worldwide.
• ResearchDxcoreChannel Partner/ Reseller/ DistributorLicence and Supply Agreement for INOVIQ's EXO-NET® pan-exosome capture product to provide EXO-NET® enabled high-throughput exosome isolation, biomarker discovery and diagnostics development services in the USA. Master Service Agreement to develop and validate INOVIQ's SubB2M tests for detection of breast and ovarian cancers.
• MP BiomedicalscoreTechnology or IntegrationMaster Manufacturing Agreement with Singapore-based MP Biomedicals for contract manufacture of cGMP-grade SubB2M Protein for INOVIQ's SubB2M tests.
• University of Queensland Research (UniQuest)coreStrategic or Co-development PartnerResearch and Option Agreement with UniQuest for EXO-NET® enabled exosome isolation and biomarker identification, and development of an earlier detection test for ovarian cancer. Prof Carlos Salomon from UQ leads the translational exosome research program.
• Griffith University Institute for GlycomicscoreStrategic or Co-development PartnerCollaborative Research Agreement for development of SubB2M pan-cancer probe assays for detection of a range of cancers using INOVIQ's SubB2M technology.
• Percorso Life SciencesminorChannel Partner/ Reseller/ DistributorService Agreement to provide US-based contract sales and logistics services for INOVIQ products.

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• System Biosciences (SBI): SBI specialises in exosome research tools including isolation kits, engineered exosomes, and EV characterisation reagents, directly overlapping with INOVIQ's EXO-NET product line. Both companies serve the translational exosome research market with reagents for biomarker discovery.
• Bio-Techne: Bio-Techne is a leading life sciences tools company offering exosome isolation reagents, ELISA kits, and proteomic analytical products that directly compete with INOVIQ's EXO-NET pan-exosome capture platform. Both companies serve academic and biopharma researchers developing EV-based diagnostics and biomarker discovery workflows.
• Miltenyi Biotec: Miltenyi Biotec develops magnetic bead-based cell and exosome isolation technologies (MACS technology) that are highly analogous to INOVIQ's immuno-magnetic EXO-NET capture system. Both companies target translational research and clinical diagnostics customers with scalable, high-purity EV isolation workflows.

Emerging players

• GRAIL: GRAIL is developing Galleri, a multi-cancer early-detection blood test targeting asymptomatic adults, the same clinical positioning and patient segment that INOVIQ's EXO-OC ovarian cancer test aims to address. GRAIL is more advanced clinically and commercially but operates at a far larger scale, establishing the strategic context for INOVIQ's ovarian screening opportunity.
• Personalis: Personalis is a cancer genomics company offering NeXT Personal for MRD detection and other oncology diagnostics, competing in the broader liquid biopsy space where INOVIQ's exosome-based tests are positioned. Both target biopharma and clinical oncology customers with advanced cancer detection assays.

Broad incumbents

• Natera: Natera is a molecular diagnostics company offering Signatera for MRD monitoring and other cfDNA-based oncology tests that target similar clinical use cases as INOVIQ's SubB2M-based breast cancer test. Both companies serve oncologists with blood-based cancer detection and monitoring tools.
• Guardant Health: Guardant Health is an established liquid biopsy company offering Guardant360 CDx for advanced cancer and early-detection programs, using cfDNA-based approaches that are an alternative modality to INOVIQ's exosome-based diagnostics. Both target oncologists and clinical labs for cancer detection and monitoring applications.
• Exact Sciences: Exact Sciences is a leading cancer screening and diagnostics company with Cologuard and Oncotype DX, providing a benchmark for the commercial pathway INOVIQ aims to follow with EXO-OC. Both companies focus on non-invasive cancer detection with blood- or stool-based assays.
• NeoGenomics: NeoGenomics is a cancer-focused clinical laboratory services company offering diagnostic, prognostic, and monitoring tests that complement hospital and oncology workflows similar to where INOVIQ's hTERT ICC and pipeline cancer tests are positioned. Both serve pathologists and oncologists with specialty oncology testing.

Others

• Lonza Group: Lonza is a leading CDMO with exosome and cell therapy manufacturing capabilities that are directly relevant to INOVIQ's CAR-exosome therapeutic program. As INOVIQ advances its preclinical CAR-exosome pipeline, Lonza represents a potential manufacturing partner comparable to INOVIQ's existing MP Biomedicals cGMP manufacturing agreement for SubB2M.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/watch?v=208L0r4tXQ0
• LinkedInlinkedin.com/company/bard1

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about INOVIQ Ltd (ASX:IIQ)